0 3 The the DT 4 21 carboxyl-terminal carboxyl-terminal JJ 22 33 cytoplasmic cytoplasmic JJ 34 40 domain domain NN 41 43 of of IN 44 48 CD36 CD36 NNP 49 51 is be VBZ 52 60 required require VBN 61 64 for for IN 65 73 oxidized oxidize VBN 74 85 low-density low-density JJ 86 97 lipoprotein lipoprotein NN 98 108 modulation modulation NN 109 111 of of IN 112 121 NF-kappaB NF-kappaB NNP 122 130 activity activity NN 131 133 by by IN 134 139 tumor tumor NN 140 148 necrosis necrosis NN 149 161 factor-alpha factor-alpha NN 161 162 . . . 164 167 The the DT 168 175 binding binding NN 176 178 of of IN 179 187 oxidized oxidize VBN 188 199 low-density low-density JJ 200 211 lipoprotein lipoprotein NN 212 213 ( ( ( 213 215 Ox Ox NNP 216 219 LDL LDL NNP 219 220 ) ) ) 221 223 by by IN 224 244 monocyte-macrophages monocyte-macrophage NNS 245 251 causes cause VBZ 252 263 pleiotropic pleiotropic JJ 264 271 effects effect NNS 271 272 , , , 273 282 including include VBG 283 290 changes change NNS 291 293 in in IN 294 298 gene gene NN 299 309 expression expression NN 309 310 , , , 311 314 and and CC 315 317 is be VBZ 318 325 thought think VBN 326 328 to to TO 329 338 represent represent VB 339 341 an an DT 342 347 early early JJ 348 353 event event NN 354 356 in in IN 357 370 atherogenesis atherogenesis NN 370 371 . . . 372 375 The the DT 376 384 integral integral JJ 385 393 membrane membrane NN 394 406 glycoprotein glycoprotein NN 407 411 CD36 cd36 NN 412 419 appears appear VBZ 420 422 to to TO 423 427 play play VB 428 429 a a DT 430 443 physiological physiological JJ 444 448 role role NN 449 451 in in IN 452 459 binding binding NN 460 463 and and CC 464 470 uptake uptake NN 471 473 of of IN 474 476 Ox Ox NNP 477 480 LDL LDL NNP 481 483 by by IN 484 504 monocyte-macrophages monocyte-macrophage NNS 504 505 , , , 506 514 although although IN 515 518 the the DT 519 528 molecular molecular JJ 529 535 events event NNS 536 546 associated associate VBN 547 551 with with IN 552 559 CD36-Ox CD36-Ox NNP 560 563 LDL LDL NNP 564 575 interaction interaction NN 576 579 are be VBP 580 587 unknown unknown JJ 587 588 . . . 589 591 To to TO 592 600 approach approach VB 601 605 this this DT 606 611 issue issue NN 611 612 , , , 613 615 we we PRP 616 620 used use VBD 621 625 CD36 CD36 NNP 626 637 transfected transfecte VBN 638 645 Chinese chinese JJ 646 654 hampster hampster NN 655 660 ovary ovary NN 661 662 ( ( ( 662 665 CHO CHO NNP 665 666 ) ) ) 667 672 cells cell NNS 672 673 , , , 674 681 exposed expose VBD 682 686 them them PRP 687 689 to to TO 690 692 Ox Ox NNP 693 696 LDL LDL NNP 696 697 , , , 698 701 and and CC 702 712 determined determine VBN 713 720 changes change NNS 721 723 in in IN 724 727 the the DT 728 736 activity activity NN 737 739 of of IN 740 743 the the DT 744 757 transcription transcription NN 758 764 factor factor NN 765 774 NF-kappaB nf-kappab NN 774 775 . . . 776 778 We we PRP 779 785 report report VBP 786 790 here here RB 791 795 that that IN 796 798 Ox Ox NNP 799 802 LDL LDL NNP 803 811 enhanced enhance VBD 812 815 DNA dna NN 816 823 binding binding NN 824 832 activity activity NN 833 835 of of IN 836 843 nuclear nuclear JJ 844 852 extracts extract NNS 853 855 to to TO 856 858 an an DT 859 868 NF-kappaB NF-kappaB NNP 869 877 sequence sequence NN 878 887 following follow VBG 888 898 activation activation NN 899 901 of of IN 902 916 CD36-producing cd36-producing JJ 917 920 CHO CHO NNP 921 926 cells cell NNS 927 931 with with IN 932 935 the the DT 936 951 proinflammatory proinflammatory JJ 952 960 cytokine cytokine NN 961 966 tumor tumor NN 967 975 necrosis necrosis NN 976 988 factor-alpha factor-alpha NN 989 990 ( ( ( 990 999 TNF-alpha TNF-alpha NNP 999 1000 ) ) ) 1000 1001 . . . 1002 1006 This this DT 1007 1015 enhanced enhance VBN 1016 1019 DNA dna NN 1020 1027 binding binding NN 1028 1036 activity activity NN 1037 1040 was be VBD 1041 1050 inhibited inhibit VBN 1051 1053 by by IN 1054 1066 coincubation coincubation NN 1067 1069 of of IN 1070 1074 CD36 CD36 NNP 1075 1086 transfected transfecte VBN 1087 1092 cells cell NNS 1093 1097 with with IN 1098 1101 the the DT 1102 1107 human human JJ 1108 1121 CD36-specific cd36-specific JJ 1122 1130 antibody antibody NN 1131 1135 OKM5 okm5 NN 1135 1136 . . . 1137 1139 We we PRP 1140 1144 also also RB 1145 1155 determined determine VBD 1156 1160 that that IN 1161 1171 activation activation NN 1172 1174 of of IN 1175 1184 NF-kappaB NF-kappaB NNP 1185 1188 DNA DNA NNP 1189 1196 binding binding NN 1197 1205 activity activity NN 1206 1214 required require VBD 1215 1217 an an DT 1218 1224 intact intact JJ 1225 1242 carboxyl-terminal carboxyl-terminal JJ 1243 1254 cytoplasmic cytoplasmic JJ 1255 1262 segment segment NN 1263 1265 on on IN 1266 1270 CD36 CD36 NNP 1270 1271 . . . 1272 1275 Our our PRP$ 1276 1283 results result NNS 1284 1291 support support VBP 1292 1295 the the DT 1296 1300 idea idea NN 1301 1305 that that IN 1306 1311 human human JJ 1312 1316 CD36 cd36 NN 1317 1325 mediates mediate VBZ 1326 1332 signal signal NN 1333 1345 transduction transduction NN 1346 1352 events event NNS 1353 1355 in in IN 1356 1364 response response NN 1365 1367 to to TO 1368 1370 Ox Ox NNP 1371 1374 LDL LDL NNP 1374 1375 . . .